Comparative Risk of Acute Kidney Injury Following Concurrent Administration of Vancomycin with Piperacillin/Tazobactam or Meropenem: A Systematic Review and Meta-Analysis of Observational Studies

Abdulmajeed M. Alshehri, Mohammed Y. Alzahrani, Mohammed A. Abujamal, Mariam H. Abdalla, Shuroug A. Alowais, Osamah M. Alfayez, Majed S. Alyami, Abdulaali R. Almutairi, and Omar A. Almohammed

Abstract: The study aims to comparatively assess the nephrotoxicity of vancomycin when combined with piperacillin-tazobactam (V + PT) or meropenem (V + M) in adult patients hospitalized in general wards or intensive care units. We searched MEDLINE, Google Scholar, and Web of Science for observational studies evaluating incidences of AKI in adult patients receiving V + PT or V + M for at least 48 h in general wards or intensive care units. The primary outcome was AKI events, while the secondary outcomes were hospital length of stay, need for renal replacement therapy (RRT), and mortality events. The odds ratio (OR), or mean difference for the hospital length of stay, with a corresponding 95% confidence interval (CI) from the inverse variance weighting random-effects model were estimated for the risk of AKI, RRT, and mortality. Of the 112 studies identified, twelve observational studies were included in this meta-analysis with a total of 14,511 patients. The odds of having AKI were significantly higher in patients receiving V + PT compared with V + M (OR = 2.31; 95%CI 1.69–3.15). There were no differences between V + PT and V + M in the hospital length of stay, having AKI were significantly higher in patients receiving V + PT compared with V + M (OR = 2.31; 95%CI 1.69–3.15). There were no differences between V + PT and V + M in the hospital length of stay, RRT, or mortality outcomes. Thus, clinicians should be vigilant while using V + PT, especially in patients who are at high risk of AKI.

Keywords: acute kidney injury; vancomycin; piperacillin-tazobactam; meropenem; nephrotoxicity

1. Introduction

Vancomycin has good activity against Gram-positive pathogens and can be used for multiple types of infection. However, it is known for its risk of causing acute kidney injury (AKI) by inducing acute interstitial nephritis and/or acute tubular necrosis [1]. The risk of vancomycin-induced AKI has been widely reported and ranges between 5 and 7% [1]. Incidences of AKI are associated with increased health-related costs, prolonged length of hospitalization, and higher mortality and morbidity rate, especially among hospitalized patients [2–7]. Several risk factors for vancomycin-induced AKI are known, for example, the dose of vancomycin, duration of therapy, plasma level, age of patient, comorbidities, concurrent use of other nephrotoxic agents, and admission to the intensive care unit [8–14].
The combination of vancomycin/piperacillin-tazobactam (V + PT) is one of the most commonly used broad-coverage antibiotics in hospitals [12]. It provides activity against anaerobic bacteria, Gram-negative pathogens, including Pseudomonas aeruginosa, and Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA). However, several studies have assessed the nephrotoxic effect of V + PT in patients treated in critical and non-critical care settings and found it to be associated with an increased risk of developing AKI [13–31]. Consequently, the use of other antipseudomonal beta-lactam antibiotics, such as cefepime and meropenem, was suggested alongside of vancomycin as an alternative for V + PT to avoid or minimize the risk of AKI.

Several studies have investigated the difference in the nephrotoxic effect for vancomycin when it is combined with either PT or other antipseudomonal beta-lactam antibiotics [21,28,30–39]. Moreover, conflicting results were reported regarding the incidences of AKI with V + PT compared to vancomycin/meropenem (V + M). Therefore, this meta-analysis seeks to evaluate the nephrotoxic effect of V + PT in comparison to V + M.

2. Materials and Methods
2.1. Data Source and Search Strategy

A systematic search was conducted using MEDLINE, Google Scholar, and Web of Science to identify observational studies evaluating incidences of AKI in adult patients receiving V + PT or V + M between January 2017 and November 2021. Search terms included piperacillin-tazobactam, vancomycin, meropenem, acute kidney injury, and nephrotoxicity. Moreover, bibliographies of recent reviews and meta-analyses were manually searched to identify further studies.

2.2. Study Selection

We included observational studies published in peer-reviewed journals and reported the incidences of AKI in patients receiving V + PT versus V + M for at least 48 h (Table S1). Studies published in a non-English language or published as an abstract were excluded. Two investigators (MAA and MSA) combined the citations generated from searching the databases and removed the duplicates, then screened the title and abstracts independently. The assessment of the full text articles for inclusion was completed by two independent investigators (MAA and MSA) and verified by a third investigator (MHA).

2.3. Data Extraction, Risk of Bias Assessment, and Statistical Analysis

For each study, the first author’s name, study design, sample size, study location, year of publication, clinical setting (intensive care units (ICU) or non-ICU), and AKI definition used were extracted. We also extracted data on the primary outcome of interest: incidences of AKI, as well as the secondary outcomes (length of stay (LOS) in hospital, renal replacement therapy (RRT), and mortality) and the factors included in the adjusted analysis. The risk of bias assessment was conducted for each study using the Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis by two independent investigators (MAA and MSA) [40]. The odds ratio (OR) with the corresponding 95% confidence interval (CI) from the inverse variance weighting random-effects model was estimated for the risk of AKI, RRT, and mortality. The mean difference was estimated using the inverse variance weighting random-effects model to estimate the difference in the LOS in hospitals between V + PT and V + M users. Heterogeneity was assessed using $I^2$ statistics. We also conducted a subgroup analysis based on the clinical setting (ICU, non-ICU, or both). Moreover, we conducted a sensitivity analysis for studies that involve adjustment for potential confounders to estimate the adjusted odds ratio (aOR) for AKI. All the analyses were conducted using the RevMan 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark). This meta-analysis was prepared following the preferred reporting system for meta-analysis of observational studies (MOOSE) [41].
3. Results

3.1. Study Characteristics

A total of 112 observational studies were initially identified in the literature search, twelve of which were included in this meta-analysis, with a total of 14,511 patients [21,28,30–39]. One-hundred studies were excluded based on population, measured outcomes, and relevancy to the objective of the meta-analysis (Figure 1). The sample size for the included studies ranged between 76 and 10,236 patients (Table 1). Of the included studies, eleven were retrospective in nature and one was prospective. Four studies were conducted including both critically and non-critically ill patient populations, while five studies were conducted including non-critically ill patients and three included critically ill patients from the ICU only. Six studies used the Kidney Disease Improving Global Outcomes (KDIGO) criteria for AKI definition [42]; two used the Acute Kidney Injury Network (AKIN) criteria [43]; one used the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) criteria [44], whereas three studies used pre-specified criteria, defined as an increase in serum creatinine by 0.5 mg/dL or 50% above the baseline. The NOS score for all included studies was 7–9 (Table S2).

![Flow diagram for selection of studies included in the meta-analysis](image_url)
Table 1. Studies that were included in the systematic review and meta-analysis.

| Study                          | Year | Type               | Country | AKI Definition                                                                 | Proportion of Critically Ill Patients | Patients with AKI History or CKD | Sample Size | Incidence V + PT | Incidence V + M | p-Value |
|-------------------------------|------|--------------------|---------|--------------------------------------------------------------------------------|--------------------------------------|----------------------------------|------------|------------------|------------------|---------|
| Alyami et al.                 | 2017 | Retrospective cohort | USA     | KDIGO An absolute 0.5 mg/dL increase in SCr or at least 50% increase in SCr from baseline | 17.5% Excluded                       |                                  | 183        | 8/108 (7.4%)     | 4/75 (5.3%)      | 0.4     |
| Cannon et al.                 | 2018 | Retrospective cohort | USA     | An absolute 0.5 mg/dL increase in SCr or at least 50% increase in SCr from baseline | 18.9% Excluded                       |                                  | 366        | 74/292 (25.3%)   | 8/74 (9.5%)      | 0.008   |
| Tookhi et al.                 | 2021 | Retrospective cohort | SA      | KDIGO                                            | 24.6% Excluded                       |                                  | 158        | 8/77 (10.3%)     | 17/81 (20.9%)    | 0.07    |
| Rungkitwattanakul et al.      | 2021 | Retrospective cohort | USA     | KDIGO                                            | N/A Excluded                         |                                  | 207        | 16/74 (21.6%)    | 5/67 (7.4%)      | 0.002   |

**Studies including critically and non-critically ill patients**

| Study                          | Year | Type               | Country | AKI Definition                                                                 | Proportion of Critically Ill Patients | Patients with AKI History or CKD | Sample Size | Incidence V + PT | Incidence V + M | p-Value |
|-------------------------------|------|--------------------|---------|--------------------------------------------------------------------------------|--------------------------------------|----------------------------------|------------|------------------|------------------|---------|
| Balci et al.                  | 2018 | Retrospective cohort | Turkey  | AKIN An absolute 0.5 mg/dL increase in SCr or at least 50% increase in SCr from baseline | NA                                   |                                  | 132        | 26/63 (41.3%)    | 7/69 (10.1%)     | <0.001  |
| Robertson et al.              | 2018 | Retrospective cohort | USA     | NA Excluded                                                                       | 169                                  | 14/85 (16.5%)                    | 3/84 (3.6%) |                  |                  | 0.009   |
| Mullins et al.                | 2018 | Prospective cohort  | USA     | NA Excluded                                                                       | 143                                  | 28/94 (29.8%)                    | 7/49 (14.3%)|                  |                  | <0.001  |
| Rutter et al.                 | 2019 | Retrospective cohort | USA     | RIFLE within first 7 days of antimicrobial therapy                                | NA                                   |                                  | 10,236     | 2713/9898 (27.4%)| 52/338 (15.4%)  | <0.001  |
| Ide et al.                    | 2019 | Retrospective cohort | Japan   | KDIGO Not reported                                                                 | 76                                   | 9/27 (33.3%)                     | 4/49 (8.2%) |                  |                  | 0.015 * |

**Studies including critically ill patients only**

| Study                          | Year | Type               | Country | AKI Definition                                                                 | Proportion of Critically Ill Patients | Patients with AKI History or CKD | Sample Size | Incidence V + PT | Incidence V + M | p-Value |
|-------------------------------|------|--------------------|---------|--------------------------------------------------------------------------------|--------------------------------------|----------------------------------|------------|------------------|------------------|---------|
| Schreier et al.               | 2019 | Retrospective cohort | USA     | AKIN                                                                                   | 100%                                 |                                  | 1926       | 601/1540 (39.0%)  | 135/386 (34.9%) | 0.49    |
| Blevins et al.                | 2019 | Retrospective cohort | USA     | KDIGO                                                                                   | 100%                                 |                                  | 758        | 144/366 (39.3%)  | 92/392 (23.5%)  | <0.0001 |
| Kang et al.                   | 2019 | Retrospective cohort | SK      | KDIGO                                                                                   | 100%                                 |                                  | 157        | 39/74 (52.7%)    | 23/83 (27.7%)   | <0.0001 |

Abbreviation: AKI: acute kidney injury; CKD: chronic kidney disease; V + PT: vancomycin/piperacillin-tazobactam; V + M: vancomycin/meropenem; SCr: serum creatinine; KDIGO: kidney disease improving global outcomes; RIFLE: risk, injury, failure, loss, and end-stage renal failure; AKIN: acute kidney injury network; SA: Saudi Arabia; SK: South Korea. * p-value for carbapenem group not meropenem only.
3.2. Outcomes from the Main Analysis

3.2.1. AKI

The pooled analysis for studies reporting the risk of AKI indicated that the odds of developing AKI were significantly higher in patients who received V + PT versus those who received V + M (OR = 2.31; 95%CI 1.69–3.15, I² = 59%; Figure 2). The pooled analysis of the aORs also showed increased odds of AKI following the use of V + PT versus V + M (aOR 2.72; 95%CI 1.82–4.07, I² = 55%; Figure S1).

| Study or Subgroup | vancomycin+piperacillin tazobactam | vancomycin + meropenem | Odds Ratio | Odds Ratio |
|-------------------|----------------------------------|-----------------------|------------|------------|
| Vancomycin 2017   | 0.350857 | 0.652866 | 108 | Total 75 | 4.6% | 1.42 [0.41, 4.91] |
| Balco 2018        | 1.108563 | 0.331093 | 63 | Total 69 | 10.0% | 3.03 [1.58, 5.88] |
| Blevins 2019      | 0.751416 | 0.153981 | 292 | Total 392 | 15.0% | 2.12 [1.55, 2.90] |
| Cannon 2019       | 1.029816 | 0.398742 | 292 | Total 74 | 8.4% | 2.80 [1.28, 6.12] |
| Ide 2019          | 1.728109 | 0.661733 | 27 | Total 49 | 4.3% | 5.63 [1.54, 20.60] |
| Kang 2019         | 1.238976 | 0.463381 | 74 | Total 83 | 7.1% | 3.45 [1.39, 8.56] |
| Mullins 2018      | 0.883768 | 0.46739  | 94 | Total 47 | 7.0% | 2.42 [0.97, 6.05] |
| Robertson 2018    | 1.924249 | 0.717345 | 85 | Total 84 | 3.4% | 6.85 [1.51, 31.08] |
| Rungkhettarakul, 2021 | 1.9502 | 0.6491 | 74 | Total 67 | 4.5% | 7.03 [1.97, 25.09] |
| Rutter 2019       | 0.929219 | 0.190272 | 9489 | Total 338 | 14.3% | 2.53 [1.62, 3.52] |
| Schror 2019       | 0.405465 | 0.201731 | 1540 | Total 386 | 13.8% | 1.50 [1.01, 2.23] |
| Tokhi 2021        | -0.82098 | 0.45708 | 77 | Total 81 | 7.2% | 0.44 [0.18, 1.08] |
| Total (95% CI)    | 12698   | 1745 100.0% | 2.31 [1.89, 3.18] |

Figure 2. Acute kidney injury (AKI).

3.2.2. LOS in Hospital

Although there was a mean difference of approximately half a day between the two groups in favor of the V + PT group, this difference between the groups did not reach statistical significance (MD = −0.48 day; 95%CI −2.00–1.04, I² = 73%; Figure 3).

Figure 3. Length of stay (LOS) in hospital.

3.2.3. Renal Replacement Therapy (RRT)

A total of 14 patients in the V + PT group required RRT compared with 6 patients in the V + M group. However, this difference between the two groups was not statistically significant (OR = 1.15; 95%CI 0.40–3.27, I² = 0%; Figure 4).

Figure 4. Renal replacement therapy (RRT).
3.2.4. Mortality

The rate of mortality was 11.6% in the V + PT group compared with 15.0% in the V + M group, but this difference was not statistically significant (OR = 0.76; 95%CI 0.46–1.24, \(I^2 = 62\%\); Figure 5).

![Figure 5. Mortality.](image)

3.3. Outcomes from the Subgroup Analyses Based on Clinical Setting

3.3.1. AKI

The rate of AKI was statistically higher in ICU and non-ICU settings for V + PT versus V + M treated patients (OR = 1.97; 95%CI 1.39–2.79, \(I^2 = 43\%\), and OR = 2.78; 95%CI 2.12–3.64, \(I^2 = 0\%\), respectively; Figure S2). In addition, four studies combined data for patients from both clinical settings. The pooled analysis of these studies showed no statistical difference in the risk of AKI between V + PT and V + M with significant heterogeneity (OR = 1.81; 95%CI 0.57–5.68, \(I^2 = 80\%\); Figure S2). After restricting the analysis to studies that reported an adjusted analysis for potential confounders, the risk of AKI in the ICU setting was not significant (aOR = 2.05; 95%CI 0.93–4.52, \(I^2 = 63\%\); Figure S3). Only one study presented a significant increase in the odds of AKI among V + PT versus V + M users in patients treated in ICU and non-ICU settings with (aOR = 7.03; 95%CI 1.97–25.09; Figure S3).

3.3.2. LOS in Hospital

The LOS was not statistically different between V + PT and V + M users based on the clinical setting (Figure S4).

3.3.3. Renal Replacement Therapy (RRT)

The subgroup analysis based on the clinical setting did not show a difference in the risk of RRT between V + PT users and V + M users (Figure S5).

3.3.4. Mortality

The subgroup analysis included only two studies in the non-ICU setting, and their pooled analysis did not show a difference in mortality between V + PT and V + M users (Figure S6). There was only one study in the ICU setting subgroup and one study in the combined ICU and non-ICU setting subgroup. These studies showed a reduction in the risk of mortality among V + PT users compared to V + M users (Figure S6).

4. Discussion

This meta-analysis sought to evaluate the nephrotoxic effect when using vancomycin in combination with either piperacillin/tazobactam or meropenem. The use of vancomycin combined with piperacillin/tazobactam was associated with a higher risk of AKI compared to the use of vancomycin combined with meropenem. However, no difference between the two combinations was observed in the hospital LOS, need for RRT, or mortality. In this meta-analysis, 11 of the 12 included studies showed higher rates of AKI when using V + PT compared to V + M. Although the study by Tookhi et al. reported a contrasting result, higher odds of AKI with V + M compared to V + PT [38], this deviation could be due to the higher number of critically ill patients in the V + M compared to the V + PT group. However, this difference was not statistically significant.
The findings from the overall analyses of the risk of AKI were consistent with those from previous meta-analyses that compared the use of V + PT to vancomycin combined with other beta-lactams; in fact, patients on V + PT had a higher risk of AKI compared to patients on other combinations [45,46]. The meta-analysis of Chen et al. included eight observational studies comparing the risk of AKI in patients receiving V + PT versus patients on vancomycin in combination with either cefepime, meropenem, or cefepime with tobramycin. They found that the use of V + PT was associated with an increase in the risk of AKI compared to the use of vancomycin in combination with meropenem or cefepime [45]. In addition, Giuliano et al. analyzed the results of fifteen observational studies assessing the risk of AKI in patients receiving V + PT versus vancomycin monotherapy or in combination with other antibiotics. Their findings were also consistent with our findings, as the risk of AKI associated with the use of the V + PT combination was significantly higher compared to the use of vancomycin monotherapy or in combination with other antibiotics [46].

Several efforts and recommendations have been proposed in practice to prevent or minimize the risk of AKI while using vancomycin. Examples of preventive measures include hydration, avoiding the concomitant use of other nephrotoxic medications such as NSAIDs, and therapeutic drug monitoring to assure the appropriateness of the vancomycin dose [47]. The result from this study suggests the need for vigilant assessment before using V + PT when possible, to help reduce the risk of AKI in high-risk patients. However, the study does not suggest that using meropenem can result in a lower risk of AKI compared to other beta-lactam antibiotics, such as cefepime; thus, further studies are needed to answer this question.

The main limitation of this meta-analysis is the inclusion of several studies with a heterogeneous population. However, several sub-analyses were conducted to drive the right conclusion. In addition, there were variations in the AKI definition across the included studies. However, all criteria used for defining AKI are commonly used in practice and research; thus, the variation may not affect this study’s conclusions. Although most of the evaluated studies were retrospective, the combined analysis of these studies was justified by the lack of randomized clinical trials evaluating the impact of different combinations on the risk of developing AKI and the fact that retrospective observational studies may provide the best available evidence for practice and data for future research. Nevertheless, our results should be interpreted carefully, and a reasonable assessment of these results should be considered.

5. Conclusions

The accumulating evidence suggests that V + PT is associated with an increased risk of AKI compared to vancomycin alone or in combination with other beta-lactam antibiotics [48]. This meta-analysis revealed that the V + PT combination is associated with a greater risk of developing AKI than is V + M. Thus, clinicians should be vigilant when using V + PT, especially in patients with a high risk of AKI.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics11040526/s1, Table S1. Summary of inclusion criteria; Table S2. Newcastle–Ottawa scale for assessing the quality of included studies; Figure S1. Acute kidney injury (AKI); pooled analysis of the adjusted odds ratio (aOR); Figure S2. Acute kidney injury (AKI) based on clinical setting; Figure S3. Acute kidney injury (AKI) based on clinical setting for studies reported adjusted analysis for potential confounders; Figure S4. Length of stay (LOS) in hospital based on clinical setting. Figure S5. Renal replacement therapy (RRT) based on clinical setting; Figure S6. Mortality based on clinical setting.

Author Contributions: Conceptualization, M.S.A. and O.A.A.; methodology, A.R.A.; software, A.R.A.; validation, A.R.A., M.S.A. and O.A.A.; formal analysis, A.R.A.; investigation, M.S.A.; resources, M.S.A.; writing—original draft preparation, A.M.A., M.Y.A., M.A.A., M.H.A. and S.A.A.; writing—review and editing, M.S.A., O.A.A., A.R.A. and O.M.A.; supervision, M.S.A., O.A.A., A.R.A. and O.M.A.; project administration, M.S.A., O.A.A., A.R.A. and O.M.A.; funding acquisition, O.A.A. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by Researcher Supporting Project (RSP-2021/77), King Saud University, Riyadh, Saudi Arabia.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to extend their appreciation to King Saud University for funding the publication of this work through the Researcher Supporting Project (RSP-2021/77), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest: The authors declare no conflict of interest.

Disclaimer: The contents of this manuscript are solely the authors’ views and may not be understood or quoted as being made on behalf of reflecting the position of the Saudi Food and Drug Authority.

References
1. Sawada, A.; Kawanishi, K.; Morikawa, S.; Nakano, T.; Kodama, M.; Mitobe, M.; Taneda, S.; Koike, J.; Ohara, M.; Nagashima, Y.; et al. Biopsy-proven vancomycin-induced acute kidney injury: A case report and literature review. *BMC Nephrol.* 2018, 19, 72. [CrossRef] [PubMed]
2. Dasta, J.F.; Kane-Gill, S. Review of the Literature on the Costs Associated with Acute Kidney Injury. *Pharmacotherapy* 2008, 73, 1008–1016. [CrossRef] [PubMed]
3. Wang, H.E.; Muntner, P.; Chertow, D.G. Acute kidney injury and mortality in hospitalized patients. *Am. J. Nephrol.* 2012, 35, 349–355. [CrossRef] [PubMed]
4. Liangos, O.; Wald, R.; O’Bell, J.W.; Price, L.; Pereira, B.J.; Jaber, B.L. Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. *Clin. J. Am. Soc. Nephrol.* 2006, 1, 43–51. [CrossRef] [PubMed]
5. Uchino, S.; Kellum, J.A.; Bellomo, R.; Doig, G.S.; Morimatsu, H.; Morgera, S.; Schetz, M.; Tan, I.; Bouman, C.; Macedo, E.; et al. Acute renal failure in critically ill patients: A multinational, multicenter study. *JAMA* 2005, 294, 813–818. [CrossRef]
6. Chertow, G.M.; Burdick, E.; Honour, M.; Bonventre, J.V.; Bates, D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J. Am. Soc. Nephrol.* 2005, 16, 3365–3370. [CrossRef]
7. Metnitz, P.G.H.; Krenn, C.G.; Steltzer, H.; Lang, T.; Ploder, J.; Lenz, K.; Le Gall, J.-R.; Druml, W. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. *Crit. Care Med.* 2002, 30, 2051–2058. [CrossRef]
8. Coca, S.G.; Yalavarthy, R.; Concato, J.; Parikh, C.R. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. *Kidney Int.* 2008, 73, 1008–1016. [CrossRef] [PubMed]
9. Davies, S.W.; Guidry, C.A.; Petroze, R.T.; Hranjec, T.; Sawyer, R.G. Vancomycin and nephrotoxicity: Just another myth? *J. Trauma Acute Care Surg.* 2013, 75, 830–835. [CrossRef] [PubMed]
10. Elyasi, S.; Khalili, H.; Dashi-Khavdaki, S.; Mohammadpour, A. Vancomycin-induced nephrotoxicity: Mechanism, incidence, risk factors and special populations. A literature review. *Eur. J. Clin. Pharmacol.* 2012, 68, 1243–1255. [CrossRef]
11. Contreiras, C.; Legal, M.; Lau, T.T.; Thalakada, R.; Shalansky, S.; Ensom, M.H. Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. *Can. J. Hosp. Pharm.* 2014, 67, 126–132. [CrossRef] [PubMed]
12. Bourget, P.; Hulin, A.; Reveilé, R.; Bever, H.; Carsin, H. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. *Antimicrob. Agents Chemother.* 1996, 40, 139–145. [CrossRef] [PubMed]
13. Kim, T.; Kandiah, S.; Patel, M.; Rab, S.; Wong, J.; Xue, W.; Easley, K.; Anderson, A.M. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. *BMC Res. Notes* 2015, 8, 579. [CrossRef] [PubMed]
14. Meaney, C.J.; Hynicka, L.M.; Tsoukleris, M.G. Vancomycin-associated nephrotoxicity in adult medicine patients: Incidence, outcomes, and risk factors. *Pharmacotherapy* 2014, 34, 653–661. [CrossRef]
15. Bailie, G.R.; Neal, D. Vancomycin ototoxicity and nephrotoxicity. A review. *Med. Toxicol. Advers. Drug Exp.* 1988, 3, 376–386. [CrossRef]
16. Burgess, L.D.; Drew, R.H. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. *Pharmacotherapy* 2014, 34, 670–676. [CrossRef]
17. Gomes, D.M.; Smotherman, C.; Birch, A.; DuFree, L.; Delia Vecchia, B.J.; Kraemer, D.F.; Jankowski, C.A. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. *Pharmacotherapy* 2014, 34, 662–669. [CrossRef]
18. Moenster, R.P.; Linneman, T.W.; Finnegan, P.M.; Hand, S.; Thomas, Z.; McDonald, J.R. Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: Piperacillin-tazobactam as compared with cefepime. *Clin. Microbiol. Infect.* 2014, 20, 384–389. [CrossRef]
19. Hammond, D.A.; Smith, M.N.; Painter, J.T.; Meena, N.K.; Lusardi, K. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. *Pharmacotherapy* 2016, 36, 463–471. [CrossRef]

20. Lorenz, M.A.; Moenster, R.P.; Linneman, T.W. Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure. *J. Med. Microbiol.* 2016, 65, 195–199. [CrossRef]

21. Al Yami, M.S. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem. *J. Infect. Public Health* 2017, 10, 770–773. [CrossRef] [PubMed]

22. Navalkele, B.; Pogue, J.M.; Karino, S.; Nishan, B.; Salim, M.; Solanki, S.; Pervaiz, A.; Tashtouh, N.; Shaikh, H.; Koppula, S.; et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. *Clin. Infect. Dis.* 2017, 64, 116–123. [CrossRef] [PubMed]

23. Peyko, V.; Smalley, S.; Cohen, H. Prospective Comparison of Acute Kidney Injury during Treatment with the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime and Meropenem and Vancomycin. *J. Pharm. Pract.* 2017, 30, 209–213. [CrossRef] [PubMed]

24. Rutter, W.C.; Burgess, D.R.; Talbert, J.C.; Burgess, D.S. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis. *J. Hosp. Med.* 2017, 12, 77–82. [CrossRef] [PubMed]

25. Rutter, W.C.; Cox, J.N.; Martin, C.A.; Burgess, D.R.; Burgess, D.S. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. *Antimicrob. Agents Chemother.* 2017, 61, e02089-16. [CrossRef]

26. Anderson, C.W.; Cazares, K.S.; Lustik, M.B.; Patel, S.M.; Denuzio, T.M. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility. *Mil. Med.* 2017; 182, e1773–e1778. [CrossRef]

27. Hundeshagen, G.; Herndon, D.N.; Capek, K.D.; Branski, L.K.; Voigt, C.D.; Killion, E.A.; Cambiaso-Daniel, J.; Sljivich, M.; De Crescenzo, A.; Micak, R.P.; et al. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. *Crit. Care* 2017, 21, 318. [CrossRef]

28. Robertson, A.D.; Li, C.; Hammond, D.A.; Dickey, T.A. Incidence of Acute Kidney Injury among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem. *Pharmacotherapy* 2018, 38, 1184–1193. [CrossRef]

29. Cannon, J.M.; Douce, R.W.; Grubbs, E.R.; Wills, C.B.; Khan, A.; Schmidt, E.M.; Wang, M.S. Comparison of Acute Kidney Injury during Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem. *Spartan Med. Res. J.* 2017, 2, 6440. [CrossRef]

30. Rutter, W.C.; Burgess, D.S. Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin. *Antimicrob. Agents Chemother.* 2018, 62, e00264-18. [CrossRef]

31. Schreier, D.J.; Kashani, K.B.; Sakhuja, A.; Mara, K.C.; Tootooni, M.S.; Personett, H.A.; Nelson, S.; Rule, A.D.; Steckelberg, J.M.; Tande, A.J.; et al. Incidence of Acute Kidney Injury Among Critically Ill Patients with Brief Empiric Use of Antipseudomonal β-Lactams with Vancomycin. *Clin. Infect. Dis.* 2019, 68, 1456–1462. [CrossRef] [PubMed]

32. Cannon, J.M.; Douce, R.W.; Grubbs, E.R.; Wills, C.B.; Khan, A.; Schmidt, E.M.; Wang, M.S. Comparison of Acute Kidney Injury during Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem. *Spartan Med. Res. J.* 2017, 2, 6440. [CrossRef]

33. Balci, C.; Uzun, Ö.; Arıcı, M.; Hayran, S.A.; Yüce, D.; Ünal, S. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: Should it be a concern? *Int. J. Antimicrob. Agents* 2018, 52, 180–184. [CrossRef] [PubMed]

34. Mullins, B.P.; Kramer, C.J.; Bartel, B.J.; Catlin, J.S.; Gilder, R.E. Comparison of the Nephrotoxicity of Vancomycin in Combination with Cefepime, Meropenem, or Piperacillin-Tazobactam: A Prospective, Multicenter Study. *Ann. Pharmacother.* 2018, 52, 639–644. [CrossRef] [PubMed]

35. Blevis, A.; Lashinsky, J.; McCammon, C.; Kollef, M.; Micek, S.; Juang, P. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin/Tazobactam, Cefepime, or Meropenem. *Antimicrob. Agents Chemother.* 2019, 63, e02658-18. [CrossRef]

36. Kang, S.; Park, J.; Yu, Y.M.; Park, M.S.; Han, E.; Chang, M.J. Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. *PLoS ONE* 2019, 14, e0217908. [CrossRef]

37. Ide, N.; Sato, S.; Sawaguchi, K. Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study. *YAKUGAKU ZASSHI* 2019, 139, 1609–1614. [CrossRef]

38. Tookhi, R.F.; Kabli, N.A.; Huntul, M.A.; Thabit, A.K. Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity. *Intern. Emerg. Med.* 2021, 16, 975–979. [CrossRef]

39. Rungkitwattanakul, D.; Ives, A.L.; Harriott, N.G.; Pan-Chen, S.; Duong, L. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem. *J. Chemother.* 2021, 34, 103–109. [CrossRef]

40. Wells GA, S.B.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. 2000. Available online: http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf (accessed on 11 April 2022).
41. Brooke, B.S.; Schwartz, T.A.; Pawlik, T.M. MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. *JAMA Surg.* 2021, 156, 787–788. [CrossRef]

42. Cattran, D.C.; Feehally, J.; Cook, H.T.; Liu, Z.H.; Fervenza, F.; Mezzano, S.A.; Floege, J.; Nachman, P.H.; Gipson, D.S.; Praga, M.; et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. *Kidney Int. Suppl.* 2012, 2, 139–274. [CrossRef]

43. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. *Crit. Care* 2007, 11, R31. [CrossRef] [PubMed]

44. Bellomo, R.; Ronco, C.; Kellum, J.A.; Mehta, R.L.; Palevsky, P.; Acute Dialysis Quality Initiative Workgroup. Acute renal failure—Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit. Care* 2004, 8, R204–R212. [CrossRef]

45. Chen, X.Y.; Xu, R.X.; Zhou, X.; Liu, Y.; Hu, C.Y.; Xie, X.F. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: A systematic review and meta-analysis. *Int. Urol. Nephrol.* 2018, 50, 2019–2026. [CrossRef] [PubMed]

46. Giuliano, C.A.; Patel, C.R.; Kale-Pradhan, P.B. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. *Pharmacotherapy* 2016, 36, 1217–1228. [CrossRef]

47. Watkins, R.R.; Deresinski, S. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy—What Is the Clinician to Do? *Clin. Infect. Dis.* 2017, 65, 2137–2143. [CrossRef]

48. Bellos, I.; Karageorgiou, V.; Pergialiotis, V.; Perrea, D.N. Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: A network meta-analysis. *Clin. Microbiol. Infect.* 2020, 26, 696–705. [CrossRef]